- Home
- IFRX vs AP Comparison
IFRX vs AP Comparison
Compare IFRX & AP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- AP
- Stock Information
- Founded
- IFRX 2007
- AP 1929
- Country
- IFRX Germany
- AP United States
- Employees
- IFRX N/A
- AP N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- AP Fluid Controls
- Sector
- IFRX Health Care
- AP Industrials
- Exchange
- IFRX Nasdaq
- AP Nasdaq
- Market Cap
- IFRX 65.8M
- AP 54.7M
- IPO Year
- IFRX 2017
- AP N/A
- Fundamental
- Price
- IFRX $0.78
- AP $3.06
- Analyst Decision
- IFRX Strong Buy
- AP
- Analyst Count
- IFRX 4
- AP 0
- Target Price
- IFRX $7.75
- AP N/A
- AVG Volume (30 Days)
- IFRX 850.4K
- AP 104.9K
- Earning Date
- IFRX 08-07-2025
- AP 05-12-2025
- Dividend Yield
- IFRX N/A
- AP N/A
- EPS Growth
- IFRX N/A
- AP N/A
- EPS
- IFRX N/A
- AP 0.22
- Revenue
- IFRX $140,242.00
- AP $412,355,000.00
- Revenue This Year
- IFRX $3.36
- AP N/A
- Revenue Next Year
- IFRX $100.60
- AP N/A
- P/E Ratio
- IFRX N/A
- AP $14.21
- Revenue Growth
- IFRX 30.90
- AP N/A
- 52 Week Low
- IFRX $0.71
- AP $0.74
- 52 Week High
- IFRX $2.82
- AP $3.99
- Technical
- Relative Strength Index (RSI)
- IFRX 33.05
- AP 51.74
- Support Level
- IFRX $0.81
- AP $3.06
- Resistance Level
- IFRX $0.86
- AP $3.75
- Average True Range (ATR)
- IFRX 0.06
- AP 0.27
- MACD
- IFRX -0.03
- AP -0.06
- Stochastic Oscillator
- IFRX 6.14
- AP 18.42
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About AP Ampco-Pittsburgh Corporation
Ampco-Pittsburgh Corp is manufacturing and selling engineered, specialty metal products and customized equipment. It operates in two business segments namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, and other metals whereas, the Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, and Buffalo Pumps. The company generates a majority of its revenue from the Forged and Cast Engineered Products segment. It has a business presence in the United States and other countries.